Please note – you will leave a website owned by MacroGenics, Inc.
MacroGenics is not responsible for any content on the third party website.
B7-H3, a member of the B7 family of immunomodulatory molecules, is overexpressed in a wide range of solid cancers. B7-H3 overexpression has been correlated with disease severity and poor outcome in several cancer types. Proof-of-concept studies targeting B7-H3 demonstrated that B7-H3 ADCs exhibited potent cytotoxicity in vitro and antitumor activity in vivo toward a range of B7-H3-expressing tumor cell lines. Based on these preliminary results, we have advanced our lead product candidate MGC018, a B7-H3 ADC comprised of a humanized B7-H3 mAb conjugated to a potent DNA alkylating payload via a cleavable peptide linker. We anticipate submitting the Investigational New Drug (IND) application for MGC018 in 2018.
At the 2017 AACR Annual Meeting, MacroGenics highlighted pre-clinical data for MGC018 showing a favorable preclinical profile, with strong reactivity toward tumor cells and tumor-associated vasculature, limited normal tissue reactivity, potent cytotoxicity in vitro and antitumor activity in vivo toward a range of B7-H3-expressing tumor cell lines representing several cancer types. (Learn More: AACR 2017 Poster).
MacroGenics retains full worldwide rights to MGC018.